CONCLUSIONS: In contrast to the literature, partial and complete remission rates were similar in females and males. Possibly, referral bias, or sex differences in immunosuppressive therapies or the disease course may explain part of these results. Future analysis of longitudinal data collected by the EURenOmics MN registry will allow detailed study of this and other questions regarding treatment and outcomes of MN. We aim to include more collaborating centers through the recently started rare kidney disease consortium: ERKnet.
INTRODUCTION AND AIMS: ANCA-associated vasculitis (AAV) is characterized by antibodies directed against proteinase-3 (PR3) or myeloperoxidase (MPO). The etiology and pathogenesis of AAV remains largely unknown, but there are clinical, histopathological, epidemiological and genetic differences between PR3-AAV and MPO-AAV. In Europeans PR3-AAV has been shown to be associated with HLA-DPB1*0401 and relapse of PR3-AAV seems to be associated with homozygosity for HLA-DPB1*0401 (Hilhorst et al, Arthritis Rheumatol 2017) . MPO-AAV has been found to be weakly associated with certain HLA-DQ alleles, but not with HLA-DP (Merkel et al, Arthritis Rheumatol 2017), Lyons et al, NEJM 2012) . HLA molecules present autoantigens to T cells and certain pockets of the peptide binding groove of the HLA molecule are especially important for the peptides bound (Wieczorek et al, Front Immonol 2017) . The sequence of the amino acids shaping the peptide binding groove are therefore of speciel interest.To evaluate the possible association of HLA alleles to AAV, we performed HLA typing at genomic sequence resolution of HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1 loci in a genetic homogenous Caucasian population and the association to the disease burden at onset and clinical outcomes (kidney involvement, multi-organ disease and relapse) among patients with either PR3-or MPO-AAV. Furthermore, sequence analysis of the hypervariable regions in exon 2 of HLA-DPB1 (Lauterbach et al, Tissue Antigens 2012) was applied to evaluate if specific sequences of HLA-DPB1 alleles associated to AAV contributed to the risk of autoimmune disease. METHODS: 187 AAV patients and 1074 healthy controls were HLA typed at two-field resolution. The association of HLA alleles to PR3-and MPO-AAV was analyzed. To evaluate the contribution of the dominant molecular motifs of HLA-DPB1 molecules associated with AAV, association studies for specific amino acid sequences of the hypervariable regions in exon 2 were performed. RESULTS: All patients with PR3-AAV were carriers of an HLA-DPB1*04 allele and 85% were homozygous. This differed significantly from the distribution in the control group (p<0.0001). Ninety-four percent were carriers of HLA-DPB1*0401, but the association was even stronger when HLA-DPB1*0402 and -DPB1*2301 also were included (OR 12.1, . In the hypervariable regions, HLA-DPB1*0401, -DPB1*0402 and -DPB1*2301 share amino acids in positions 8-9, 69, 76 and 84-87, but only positions 69 and 84-87 contributed significantly to disease risk. Other HLA alleles were only weakly associated with increased or reduced risk of developing PR3-AAV. Interestingly, HLA-DRB1*04 (OR 0.40, p¼0.003) were associated with reduced risk of kidney involvement in PR3-AAV. In MPO-AAV, we found only weak associations with HLA class I alleles. CONCLUSIONS: We confirm that HLA-DPB1*0401 is strongly associated with PR3-AAV and show that the association becomes even stronger when HLA-DPB1*0402 and -DPB1*2301 are included. These three HLA molecules have strong and essentiel similarities in the amino acids shaping the peptide binding groove, and the association most certainly reflects the presentation of the same autoantigen(s). independently associated with a poor renal outcome. However, this finding needs to be validated in different ethnic groups. METHODS: Biopsy-proven IgAN patients were continuous recruited from two large renal centers in China from 1989 to 2014. All patients were followed-up for more than 12 months. Crescent was defined as focal cellular or fibrocellular crescents formation. IgAN patients without detectable crescents were recruited to C0 group. Patients with crescents less than or more than 1/4 of all glomeruli were recruited to C1 or C2 group respectively. Primary outcome was defined as end stage renal disease (ESRD). RESULTS: Totally, 1134 IgAN patients were recruited in this study. There were618 (54.5%) in C0 group, 444 (39.2%) in C1 group and 72 (6.3%) in C2 group. Compared to C0 group, patients in C1 group or C2 group were younger, had more initial urine protein excretion, and presented with more severe mesangial hypercellularity, endocapillary proliferation or tubular atrophy/interstitial fibrosis compared to C0 group. After 34 months follow-up, there was 62 (10.0%), 38 (8.6%) and 10 (13.9%) ESRD occurred in C0, C1 and C2 group, respectively. By multivariable Cox regression analysis, we didn't find that patients in C1 (HR¼1.06, 95%CI 0.67-1.66) or C2 (HR¼0.84, 95%CI 0.34-2.08) had a worse renal outcome compared to those in C0. However, in patients with massive proteinuria (urine protein 3.5g/24d), C1þC2 were associated with an increased risk of ESRD after adjusting for age, gender, eGFR, MAP, pathological variables, and immunosuppressive treatment (HR¼3.12, 95% CI 1.23 to 7.92; P¼0.017). CONCLUSIONS: IgAN patients with crescents formation had more severe clinical and pathological manifestations. However, we failed to replicate the association between crescents and renal survival after one year of follow-up suggesting crescents have limited impact on long-term renal outcome.
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INTRODUCTION AND AIMS:
Focal segmental glomerulosclerosis (FSGS) is a primary glomerular disorder leading to end-stage renal disease. Key in the pathogenesis of FSGS is podocyte damage and loss which contributes to proteinuria and progression of the disease. Several lines of evidence support a role for the chemokine receptor CCR2 in the pathogenesis of FSGS. While traditionally thought of a monocyte/macrophage regulator, the direct expression of CCR2 by podocytes also has been suggested by several studies in both human and mouse kidneys. In addition, recent clinical trials have demonstrated that CCR2 antagonist rapidly and durably reduced proteinuria chronic kidney disease in diabetics, leading to the hypothesis that CCR2 may be acting directly on podocytes in a variety of podocytopathies, including FSGS. Additional work presented here supports a direct role for CCR2 in FSGS, and for CCR2 inhibition as a potential therapeutic treatment in FSGS. METHODS: CCR2 expression in kidney was examined by immunohistochemistry (IHC) and Immunofluorescence (IF) in both human patient biopsies and mouse kidneys. Pharmacological modeling of CCR2 inhibition in FSGS was investigated using a 5/6 nephrectomy murine model. Renal parameters assessed included proteinuria (urinary albumin excretion rate; urine albumin creatinine ratio, UAER/UACR), blood urea nitrogen (BUN), serum creatinine. Evidence for renal protective effects was also examined by histopathology. RESULTS: IHC and IF assessment revealed marked CCR2 expression in kidney glomerulus of human subjects with primary FSGS. In the mouse, glomerular expression of CCR2 was robust in FSGS models, validated by the lack of expression in the glomeruli of CCR2 knock-out mice. Furthermore, CCR2 in glomerulus was co-expressed with the podocyte nuclear marker WT-1in a significant fraction of WT-1 cells. In the FSGS model, CCR2 inhibition or RAAS inhibition rapidly and significantly reduced UAER/ UACR (42% -69% after one week of treatment vs vehicle treatment alone). Combination of CCR2 antagonist and RAAS blocker further reduced the UAER (92% reduction; p < 0.005 versus vehicle alone after one week of treatment). The protective effects of CCR2 inhibition were maintained for the duration of the study (5 weeks). CCR2 inhibition alone or in combination with RAAS blocker also significantly reduced serum creatinine and BUN. Histological parameters also significantly improved with CCR2 antagonist treatment with or without RAAS blocker (including inflammation, fibrosis, tubular casts and dilatation) and glomerular injury (including glomerular hypertrophy, mesangial expansion and glomerular sclerosis). WT-1 staining indicated that CCR2 inhibition therapy increased podocyte density in 5/6 nephrectomy mice. CONCLUSIONS: CCR2 is expressed in kidney glomerulus, including in at least a subset of podocytes. CCR2 inhibition provides significant and rapid renal protection in models of FSGS, as measured by improvement in renal functions and histological parameters, and thus represents a novel and mechanistically distinct approach for the potential treatment of FSGS. 
